{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:55:19Z","timestamp":1784757319470,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ijcard.2023.131168","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T11:04:30Z","timestamp":1688814270000},"page":"131168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Safety of routine protamine in the reversal of heparin in percutaneous coronary intervention: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"388","author":[{"given":"Paul Y.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Varadarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afif","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saahil","family":"Jumkhawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Allencherril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2023.131168_bb0005","series-title":"Primary Angioplasty: A Practical Guide","year":"2018"},{"key":"10.1016\/j.ijcard.2023.131168_bb0010","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/17425255.2016.1194395","article-title":"The toxicology of heparin reversal with protamine: past, present and future","volume":"12","author":"Sokolowska","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ijcard.2023.131168_bb0015","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0140-6736(18)31714-8","article-title":"Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial","volume":"392","author":"Valgimigli","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.ijcard.2023.131168_bb0020","first-page":"913","article-title":"Protamine usage following implantation of drug-eluting stents: a word of caution","volume":"71","author":"Cosgrave","year":"2008","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2023.131168_bb0025","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s11239-010-0482-4","article-title":"Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta-analysis","volume":"30","author":"De Luca","year":"2010","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.ijcard.2023.131168_bb0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ."},{"key":"10.1016\/j.ijcard.2023.131168_bb0035","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"BS","year":"2021"},{"key":"10.1016\/j.ijcard.2023.131168_bb0040","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0002-9149(97)00676-0","article-title":"In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation","volume":"80","author":"Pan","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131168_bb0045","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0002-8703(99)70248-6","article-title":"Administration of protamine after coronary stent deployment","volume":"138","author":"Briguori","year":"1999","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2023.131168_bb0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2004.11.021","article-title":"Impact of heparin neutralization by protamine on restenosis after coronary stent implantation","volume":"105","author":"Kaneda","year":"2005","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131168_bb0055","first-page":"66","article-title":"In-laboratory femoral sheath removal after heparin reversal by protamine after percutaneous coronary intervention","volume":"1","author":"Thuesen","year":"2005","journal-title":"EuroIntervention."},{"key":"10.1016\/j.ijcard.2023.131168_bb0060","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1517\/14656566.8.13.2017","article-title":"Immediate removal of femoral-sheath following protamine administration in patients undergoing intracoronary paclitaxel-eluting-stent implantation","volume":"8","author":"Rossi","year":"2007","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.ijcard.2023.131168_bb0065","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s11239-010-0481-5","article-title":"Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy","volume":"30","author":"Parodi","year":"2010","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.ijcard.2023.131168_bb0070","series-title":"Use of protamine for early removal of femoral introducers are coronary angioplasty with stent implantation","author":"Gon\u00e7alves","year":"2011"},{"key":"10.1016\/j.ijcard.2023.131168_bb0075","first-page":"22","article-title":"Early removal of the arterial sheath after percutaneous coronary intervention using the femoral approach: safety and efficacy stud","author":"Zago","year":"2014","journal-title":"Revista Brasileira de Cardiologia Invasiva"},{"key":"10.1016\/j.ijcard.2023.131168_bb0080","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1536\/ihj.17-352","article-title":"Safety of reversing anticoagulation by protamine following elective transfemoral percutaneous coronary intervention in the drug-eluting stent era","volume":"59","author":"Yamamoto","year":"2018","journal-title":"Int. Heart J."},{"key":"10.1016\/j.ijcard.2023.131168_bb0085","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1536\/ihj.20-126","article-title":"Mid-term clinical outcomes of immediate protamine use following elective percutaneous coronary interventions","volume":"61","author":"Kubota","year":"2020","journal-title":"Int. Heart J."},{"key":"10.1016\/j.ijcard.2023.131168_bb0090","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12872-022-02650-5","article-title":"Safety and efficacy of immediate heparin reversal with protamine after complex percutaneous coronary intervention","volume":"22","author":"Choi","year":"2022","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.ijcard.2023.131168_bb0095","first-page":"845","article-title":"Use of protamine for early femoral sheath removal after coronary stent angioplasty","volume":"33","author":"Kremer Diniz Goncalves","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2023.131168_bb0100","first-page":"398","article-title":"Safety of the administration of protamine after coronary stent implantation in an unselected large series of patients","volume":"32","author":"Kremer Diniz Goncalves","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2023.131168_bb0105","first-page":"844","article-title":"Protamine usage following implantation drug-eluting stents: is it safe?","volume":"33","author":"Kremer Diniz Goncalves","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2023.131168_bb0110","first-page":"531","article-title":"Short-term safety and efficacy of femoral vascular closure after percutaneous coronary intervention with combination of the boomerang(TM) device and intravenous protamine sulfate","volume":"29","author":"Chen","year":"2013","journal-title":"Acta Cardiol. Sin."},{"key":"10.1016\/j.ijcard.2023.131168_bb0115","first-page":"196","article-title":"Immediate protamine administration and sheath removal following percutaneous coronary intervention: a prospective study of 429 patients","volume":"56","author":"Ducas","year":"2002","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2023.131168_bb0120","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0002-9149(99)00843-7","article-title":"Early mobilization after protamine reversal of heparin following implantation of phosphorylcholine-coated stents in totally occluded coronary arteries","volume":"85","author":"Kuiper","year":"2000","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131168_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2022.08.206","article-title":"TCT-175 safety and complications associated with the use of protamine in percutaneous coronary intervention","volume":"80","author":"Alrayes","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131168_bb0130","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1540-8183.2011.00642.x","article-title":"Low-dose protamine to facilitate earlier sheath removal from the femoral artery after peripheral endovascular intervention","volume":"24","author":"Hanna","year":"2011","journal-title":"J. Interv. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131168_bb0135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/107424840501000401","article-title":"Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis","volume":"10","author":"Ebrahimi","year":"2005","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2023.131168_bb0140","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.amjcard.2009.12.001","article-title":"Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial)","volume":"105","author":"Parodi","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131168_bb0145","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2023.131168_bb0150","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized end point definitions for coronary intervention trials: the academic research Consortium-2 consensus document","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2023.131168_bb0155","first-page":"111","article-title":"The contemporary role of protamine in the cardiac catheterization laboratory","volume":"102","author":"Danek","year":"2023","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2023.131168_bb0160","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0002-9149(97)00437-2","article-title":"Partial reversal of heparin anticoagulation by intravenous protamine in abciximab-treated patients undergoing percutaneous intervention","volume":"80","author":"Kereiakes","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2023.131168_bb0170","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jcin.2015.03.028","volume":"8","author":"Smits","year":"2015","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2023.131168_bb0175","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0910496","article-title":"Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease","volume":"362","author":"Stone","year":"2010","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527323009750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527323009750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T21:02:13Z","timestamp":1759093333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527323009750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":34,"alternative-id":["S0167527323009750"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2023.131168","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of routine protamine in the reversal of heparin in percutaneous coronary intervention: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2023.131168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"131168"}}